| Title: |
Emerging pharmacological strategies supporting symptom management in borderline personality disorder: current evidence and future directions. |
| Authors: |
Pałuchowski, Michał; Krawczyk, Anna; Mozer, Maciej; Możarowski, Wiktor; Pietruszka, Wiktoria; Krupa, Agata; Potrykus, Maria; Klasicki, Przemysław; Mateńko, Jan; Kiełbratowska, Julia; Kwiecińska, Julia |
| Source: |
Psychiatry / Psychiatria; 2025, Vol. 22, p22-31, 10p |
| Subject Terms: |
BORDERLINE personality disorder; PHARMACOLOGY; IMPULSIVE personality; OMEGA-3 fatty acids; SYMPTOMS; CLINICAL trials; PSYCHOLOGICAL distress; KETAMINE |
| Abstract: |
Introduction: This article provides an overview of emerging pharmacotherapeutic approaches to support the management of symptoms in patients suffering from borderline personality disorder (BPD). Aim of review: BPD is a complex and severe mental disorder characterized by a pervasive pattern of emotional dysregulation, marked impulsivity, instability in interpersonal relationships, a distorted sense of self, and an increased risk of suicide. It represents a significant public health problem due to its relatively high prevalence, associated morbidity, and substantial economic burden. Despite that, there is currently no medication approved by the European Medicines Agency (EMA) or the Food and Drug Administration (FDA) specifically for BPD. Conclusions: Pharmacological agents such as omega-3 fatty acids, opioid antagonists, clonidine, ketamine or esketamine, memantine, and oxytocin demonstrate preliminary potential in targeting specific dimensions of BPD pathology. Omega-3 fatty acids may reduce impulsivity and affective instability, opioid antagonists may help reduce self-harm and impulsivity, clonidine may lower hyperarousal, ketamine and esketamine are being investigated for rapid relief from suicidal ideation and improvement in social functioning, primarily in the context of comorbid depression, and oxytocin may modulate stress responses and enhance social engagement. However, further research, particularly through well-designed, large-scale clinical trials is necessary to confirm their efficacy, assess optimal intervention parameters, and establish their role in clinical practice. The successful integration of these emerging adjunctive approaches into clinical practice has the potential to significantly improve outcomes for individuals with BPD and enhance the overall management of this debilitating disorder. [ABSTRACT FROM AUTHOR] |
| : |
Copyright of Psychiatry / Psychiatria is the property of VM Medica-VM Group (Via Medica) and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |